|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Hepatocellular carcinoma: Epidemiology, risk factors and pathogenesis显示文摘Hepatocellular carcinoma (HCC) is the commonest primary malignant cancer of the liver in the world. Given that the burden of chronic liver disease is expected to rise owing to increasing rates of alcoholism, hepatitis B and C prevalence and obesity-related fatty liver disease, it is expected that the incidence of HCC will also increase in the foreseeable future. This article summarizes the international epidemiology, the risk factors and the pathogenesis of HCC, including the roles of viral hepatitis, toxins, such as alcohol and aflatoxin, and insulin resistance. | Asmaa Ibrahim Gomaa Shahid A Khan Mireille B Toledano Imam Waked Simon D Taylor- Robinson | 2008 | World Journal of Gastroenterology2008，14，27： | 78 |
| 2 | Diagnosis of hepatocellular carcinoma显示文摘Hepatocellular carcinoma (HCC) is one of the commonest cancers worldwide, particularly in parts of the developing world, and is increasing in incidence. This article reviews the current modalities employed for the diagnosis of HCC, including serum markers, radiological techniques and histological evaluation, and summarises international guidelines for the diagnostic approach to HCC. | Asmaa I Gomaa Shahid A Khan Edward LS Leen Imam Waked Simon D Taylor-Robinson | 2009 | World Journal of Gastroenterology2009，15，11： | 44 |
| 3 | Recent advances in multidisciplinary management of hepatocellular carcinoma显示文摘The incidence of hepatocellular carcinoma(HCC) is increasing, and it is currently the second leading cause of cancer-related death worldwide. Potentially curative treatment options for HCC include resection, transplantation, and percutaneous ablation, whereas palliative treatments include trans-arterial chemoembolization(TACE), radioembolization, and systemic treatments. Due to the diversity of available treatment options and patients' presentations, a multidisciplinaryteam should decide clinical management of HCC, according to tumor characteristics and stage of liver disease. Potentially curative treatments are suitable for very-early- and early-stage HCC. However, the vast majority of HCC patients are diagnosed in later stages, where the tumor characteristics or progress of liver disease prevent curative interventions. For patients with intermediate-stage HCC, TACE and radioembolization improve survival and are being evaluated in addition to potentially curative therapies or with systemic targeted therapy. There is currently no effective systemic chemotherapy, immunologic, or hormonal therapy for HCC, and sorafenib is the only approved moleculartargeted treatment for advanced HCC. Other targeted agents are under investigation; trials comparing new agents in combination with sorafenib are ongoing. Combinations of systemic targeted therapies with local treatments are being evaluated for further improvements in HCC patient outcomes. This article provides an updated and comprehensive overview of the current standards and trends in the treatment of HCC. | Asmaa I Gomaa Imam Waked | 2015 | World Journal of Hepatology2015，7，4： | 15 |
| 4 | Highlights in pathogenesis of vitiligo显示文摘Vitiligo is a common pigmentary disorder. Many studies across decades and all over the world have attempted to illustrate the pathogenesis behind it; however, the pathogenesis of vitiligo remains elusive. This review article, we present the findings behind the most and updated theories behind this psychologically debilitating and disfiguring disease. The discussion begun with the role of genetic predisposition followed by neural theory first proposed in the 1950 s. Wehighlight the autoimmune hypothesis, followed by the reactive oxygen species model, zinc-α2-glycoprotein deficiency hypothesis, viral theory, intrinsic theory and biochemical, molecular and cellular alterations accounting for loss of functioning melanocytes in vitiligo. Many theories were elaborated to clarify vitiligo pathogenesis. It is a multifactorial disease involving the interplay of several factors. Future research is needed to clarify the interaction of these factors for better understanding of vitiligo pathogenesis and subsequent successful treatment. | Ghada F Mohammed Amal Hussein Gomaa Mohammed Saleh Al-Dhubaibi | 2015 | World Journal of Clinical Cases2015，3，3： | 13 |
| 5 | Platelet-albumin-bilirubin score - a predictor of outcome of acute variceal bleeding in patients with cirrhosis显示文摘BACKGROUND The albumin-bilirubin(ALBI)score was validated as a prognostic indicator in patients with liver disease and hepatocellular carcinoma.Incorporating platelet count in the platelet-albumin-bilirubin(PALBI)score improved validity in predicting outcome of patients undergoing resection and ablation.AIM To evaluate the PALBI score in predicting outcome of acute variceal bleeding in patients with cirrhosis.METHODS The data of 1517 patients with cirrhosis presenting with variceal bleeding were analyzed.Child Turcotte Pugh(CTP)class,Model of End-stage Liver Disease(MELD),ALBI and PALBI scores were calculated on admission,and were correlated to the outcome of variceal bleeding.Areas under the receivingoperator characteristic curve(AUROC)were calculated for survival and rebleeding.RESULTS Mean age was 52.6 years;1176 were male(77.5%),69 CTP-A(4.5%),434 CTP-B(29.2%),1014 CTP-C(66.8%);306 PALBI-1(20.2%),285 PALBI-2(18.8%),and 926 PALBI-3(61.1%).Three hundred and thirty-two patients died during hospitalization(21.9%).Bleeding-related mortality occurred in 11%of CTP-B,28%of CTP-C,in 21.8%of PALBI-2 and 34.4%of PALBI-3 patients.The AUROC for predicting survival of acute variceal bleeding was 0.668,0.689,0.803 and 0.871 for CTP,MELD,ALBI and PALBI scores,respectively.For predicting rebleeding the AUROC was 0.681,0.74,0.766 and 0.794 for CTP,MELD,ALBI and PALBI scores,respectively.CONCLUSION PALBI score on admission is a good prognostic indicator for patients with acute variceal bleeding and predicts early mortality and rebleeding. | Omar Elshaarawy Naglaa Allam Eman Abdelsameea Asmaa Gomaa Imam Waked | 2020 | World Journal of Hepatology2020，12，3： | 13 |
| 6 | 生物质成型燃料的热解燃烧特性试验研究显示文摘研究了棉杆成型块等生物质固体燃料在小型移动层上吸式热解燃烧炉中的热特性.结果表明,密度较大的棉杆成型块升温速率和降温速率均较低,挥发份的逸出时间增加,高温燃烧时间延长,炉子的热效率提高.棉杆成型块在炉胆中的充填量对可燃气体的稳定燃烧和高温火焰的持续时间影响显著.填满炉胆的棉杆成型块的燃烧性能优于棉杆,其燃烧热效率达39.3%,为棉杆的1.72倍. | 余有芳 盛奎川 Hassan Gomaa | 2005 | 浙江大学学报(农业与生命科学版)2005，31，5： | 9 |
| 7 | Validation of modified albumin-bilirubin-TNM score as a prognostic model to evaluate patients with hepatocellular carcinoma显示文摘BACKGROUND An ideal staging system for hepatocellular carcinoma(HCC)should rely on the hepatic reserve function and tumor burden.With the improvement in diagnostic and treatment strategies for HCC,in addition to recent treatment of viral hepatitis,finding a suitable assessment tool for hepatic reserve has become mandatory.AIM To validate a recently proposed modified albumin-bilirubin-TNM(mALBI-T)grade as a prognostic model for patients with HCC in Egypt.METHODS For patients diagnosed with HCC,Child-Turcotte-Pugh(CTP)score,Barcelona Clinic Liver Cancer(BCLC)stage,albumin-bilirubin(ALBI),plateltetalbumin– bilirubin(PALBI),ALBI-based BCLC,ALBI-T and mALBI-T grades were estimated.Patients were followed from time of diagnosis to date of death or date of data collection if they remained alive.Overall survival and received treatments were determined.Survival data were analyzed.RESULTS A total of 1910 patients were included(mean age,57 years;1575 males).At presentation,50.6%had CTP A,36.1%had CTP B and 13.4%had CTP C;12%had ALBI grade 1,62.3%had ALBI grade 2 and 24.7%had ALBI grade 3.Overall median survival was 13 mo;survival was better in patients with ALBI 1 than in those with ALBI 2 and 3(28.6 vs 14 and 5.8 mo,respectively,P<0.001).Patients with ALBI-T grades 0 and 1 had better survival than those with ALBI-T grades 2,3,4 and 5(P<0.001).The modified ALBI-T showed better stratification and significant improvement in prediction of survival.CONCLUSION ALBI-T grade is a superior prognostic tool that selects patients with HCC who have better liver reservoir and tumor stage.mALBI-T is a better prognostic model in patients with HCC. | Omar Elshaarawy Alzhraa Alkhatib Mostafa Elhelbawy Asmaa Gomaa Naglaa Allam Ayman Alsebaey Eman Rewisha Imam Waked | 2019 | World Journal of Hepatology2019，11，6： | 7 |
| 8 | Graphene oxide-based hydrogels as a nanocarrier for anticancer drug delivery显示文摘Graphene oxide (GO) possesses excellent mechanical strength,biocompatibility,colloidal stability,large surface area and high adsorption capability.It has driven to cancer nanotechnology to defeat cancer therapy obstacles,via integration into three-dimensional (3D) hydrogel network with biocompatible polymers as nanocomposites carrier,and controllable release of anticancer drugs.Specifically,the surface of GO affords π-π stacking and hydrophilic interactions with anticancer drugs.Additionally,modification of GO with various polymers such as natural and synthetic polymers enhances its biodegradability,drug loading,and target delivery.In this review,GO based hydrogels research accomplishments are reviewed on the aspects of crosslinking strategies,preparation methods,the model drug,polymer conjugation and modification with targeting ligands.Moreover,swelling kinetics,drug release profile and biological activity in vivo and in vitro are discussed.The biocompatibility of GO based hydrogels is also discussed from the perspective of its nano-bio interfaces.Apart from that,the clinical potential of GO based hydrogels and its major challenges are addressed in detail.Finally,this review concludes with a summary and invigorating future perspectives of GO based hydrogels for anticancer drug delivery.It is anticipated that this review can stimulate a new research gateway to facilitate the development of anticancer drug delivery by harnessing the unique properties of GO based hydrogels,such as large surface area,chemical purity,high loading capacity of drug,chemical stability,and the nature of lipophilic for cell membrane penetration. | Abdullah A.Ghawanmeh Gomaa A.M.Ali H.Algarni Shaheen M.Sarkar Kwok Feng Chong | 2019 | Nano Research2019，12，5： | 5 |
| 9 | 下颌骨截骨术位置对舌癌患者口腔功能的影响显示文摘目的比较正中或旁正中下颌骨截骨术对舌癌患者口腔功能的影响,为下颌骨截骨位置的选择提供依据。方法回顾性分析经下颌骨截骨入路进行舌颌颈联合根治及缺损修复重建的126例舌癌患者的临床资料。根据截开下颌骨位置的不同,分为下颌骨正中截骨术组(正中组,n=60)和下颌骨旁正中截骨术组(旁正中组,n=66)。术后定期随访,应用华盛顿大学生存质量问卷(UW-QOL)第四版比较2组患者术后吞咽、咀嚼和语音等口腔功能的差异。采用SPSS 24.0软件包进行统计学处理,P<0.05为差异有统计学意义。结果术后6月,正中组与旁正中组吞咽、咀嚼及语音功能评分差异均无统计学意义;术后1年,旁正中组患者吞咽和语音功能评分优于正中组(P<0.05),但咀嚼功能评分差异无统计学意义。结论经旁正中下颌骨截骨入路进行舌颌颈联合根治,术后患者口腔功能优于经正中下颌骨截骨入路。 | 吴建军 高兴 王文瑾 Aly Gomaa 陈洁 胡雅琴 翦新春 蒋灿华 | 2020 | 华西口腔医学杂志2020，38，3： | 4 |
| 10 | Nat Med:靶向两分子或有助于彻底治愈白血病显示文摘科学家在癌细胞内发现两个信号蛋白能够让癌细胞抵抗化疗。研究表明阻断这两种蛋白能够增强化疗对人类白血病小鼠模型的治疗效果。相关研究结果发表在国际学术期刊NatureMedicine上。研究人员发现在治疗中阻断c-Fos和Dusp1这两个蛋白能够治愈一些受激酶驱动且抵抗治疗的白血病和实体瘤。 | Meenu Kesarwani, Zachary Kincaid, Ahmed Gomaa, Erika Huber, Sara Rohrabaugh, Zain Siddiqui, Muhammad F Bouso, Kakajan Komurov, James C Mulloy, Jose A Cancelas, H Leighton Grimes Mohammad Azam Tahir Latif Ming Xu H Leighton Grimes Mohammad Azam | 2017 | 现代生物医学进展2017，17，17： | 4 |
| 11 | Middle East respiratory syndrome coronavirus: a comprehensive review显示文摘中东呼吸症候群 coronavirus 首先在 2012 被识别并且从那以后仍然保持不受管束。案例主要在中东,然而联系旅行的案例和爆发被报导了也发生了。医院并且病毒的 zoonotic 传播看起来是最重要的线路。感染严重、高度致命因此要求快速、有效的干预。这里,我们执行了出版文学的全面评论并且总结了病毒的传染病学。另外,我们总结了感染的 virological 方面并且考察了象种痘一样使用的动物模型并且抗病毒对它测试了。 | Mahmoud M. Shehata Mokhtar R. Gomaa Mohamed A. Ali Ghazi Kayali | 2016 | Frontiers of Medicine2016，10，2： | 4 |
| 12 | Ascites and alpha-fetoprotein improve prognostic performance of Barcelona Clinic Liver Cancer staging显示文摘AIM: To assess how ascites and alpha-fetoprotein(AFP) added to the Barcelona Clinic Liver Cancer(BCLC) staging predict hepatocellular carcinoma survival.METHODS: The presence of underlying cirrhosis, ascites and encephalopathy, Child-Turcotte-Pugh(CTP) score, the number of nodules, and the maximum diameter of the largest nodule were determined at diagnosis for 1060 patients with hepatocellular carcinoma at a tertiary referral center for liver disease in Egypt. Demographic information, etiology of liver disease, and biochemical data(including serum bilirubin, albumin, international normalized ratio, alanine and aspartate aminotransferases, and AFP) were evaluated. Staging of the tumor was determined at the time of diagnosis using the BCLC staging system; 496 patients were stage A and 564 patients were stage B. Patients with mild ascites on initial ultrasound, computed tomography, or clinical examination, and who had a CTP score ≤ 9 were included in this analysis. All patients received therapy according to the recommended treatment based on the BCLC stage, and were monitored from the time of diagnosis to the date of death or date of data collection. The effect of the presence of ascites and AFP level on survival was analyzed.RESULTS:At the time the data were censored,123/496(24.8%)and 218/564(38.6%)patients with BCLC stages A and B,respectively,had died.Overall mean survival of the BCLC A and B patients during a three-year follow-up period was 31 mo[95%confidence interval(95%CI):29.7-32.3]and 22.7mo(95%CI:20.7-24.8),respectively.The presenceof ascites,multiple focal lesions,large tumor size,AFP level and CTP score were independent predictors of survival for the included patients on multivariate analysis(P<0.001).Among stage A patients,18%had ascites,33%had AFP≥200 ng/m L,and 8%had both.Their median survival in the presence of ascites was shorter if AFP was≥200 ng/m L(19 mo vs 24 mo),and in the absence of ascites,patients with AFP≥200 ng/m L had a shorter survival(28mo vs 39 mo).For stage B patients,survival for the corresponding groups was 12,18,19 and 22 mo.The one-,two-,and three-year survival rates for stage A patients without ascites and AFP<200 ng/m L were94%,77%,and 71%,respectively,and for patients with ascites and AFP≥200 ng/m L were 83%,24%,and 22%,respectively(P<0.001).Adding ascites and AFP≥200 ng/m L improved the discriminatory ability for predicting prognosis(area under the curve,0.618vs 0.579 for BCLC,P<0.001).CONCLUSION:Adding AFP and ascites to the BCLC staging classification can improve prognosis prediction for early and intermediate stages of hepatocellular carcinoma. | Asmaa I Gomaa Alzhraa Al-Khatib Wael Abdel-Razek Mohammed Saad Hashim Imam Waked | 2015 | World Journal of Gastroenterology2015，21，18： | 3 |
| 13 | Oxidative quality and shelf life of meats显示文摘 | J.I. Gray E.A. Gomaa D.J. Buckley | 1996 | Meat Science1996，，： | 2 |
| 14 | Hepatocellular carcino- ma: current trends in world wide epidemiology, risk factors, diagnosis and therapeutics 显示文摘 | Shariff MI Cox I J Gomaa AI | 2009 | Expert Rev Gastroenterol Hep- atol2009，3，4： | 1 |
| 15 | Total laparoscopic hys- terectomy, vaginal hysterectomy and total abdominal hysterecto- my using electrosurgical bipolar vessel sealing technique: a ran- domized controlled trial 显示文摘 | Allam IS Makled AK Gomaa IA | 2015 | Arch Gynecol Obstet2015，291，6： | 1 |
| 16 | Effect of rare earth substitutions on some physical properties of Mn-Zn ferrite studied by positron annihilation lifetime spectroscopy 显示文摘 | Samy A M Mostafa N Gomaa E | 2006 | Applied Surface Science2006，252，： | 1 |
| 17 | Proven technologies manage olefin plant's spent caustic显示文摘 | Grover R Gomaa H M | 1993 | Hydrocarbon Processing1993，72，9： | 1 |
| 18 | Visible-solar-light-driven photocatalytic degradation of phenol with dye-sensitized Ti02 : Parametric and kinetic study 显示文摘 | Chowdhury P Moreira J Gomaa H | 2012 | Ind EngChem Res2012，51，12： | 1 |
| 19 | The effect of EGR rates on NOx and smoke emissions of an IDI diesel engine fuelled with Jatropha biodiesel blends显示文摘 | Gomaa M Alimin A J Kamarudin K A | | 0，，03： | 1 |
| 20 | Addition of low dose hCG to rFSh benefits older women during ovarian stimulation for IVF 显示文摘 | Gomaa H Casper RF Esfandiari N | 2012 | Re- prod Biol Endocrino12012，10，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员